ANN ARBOR, MI / ACCESSWIRE / August 4, 2023 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering diagnostic and therapeutic products for companion animals, will host a conference call and audio-only webcast on Thursday, August 10, 2023 at 4:30 p.m. ET to discuss the Company's operational and financial highlights for its second quarter ending June 30, 2023. A question-and-answer session will follow management's prepared remarks.
Event: Zomedica Q2 2023 Financial Result Conference Call
Date: Thursday, August 10, 2023
Time: 4:30 p.m. Eastern Time
Live Call: +1-888-886-7786 (U.S. Toll-Free) or +1-416-764-8658 (International)
Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1625619&tp_key=8db2f382d8
For interested individuals unable to join the conference call, a dial-in replay of the call will be available until August 24, 2023 at 11:59 p.m. ET and can be accessed by dialing +1-844-512-2921 (U.S. Toll-Free) or +1-412-317-6671 (International) and entering replay pin number: 77164792.
About Zomedica
Based in Ann Arbor, Michigan, Zomedica (NYSE American: ZOM) is a veterinary health company creating products for companion animals by focusing on the unmet needs of clinical veterinarians. Zomedica's product portfolio will include innovative diagnostics and medical devices that emphasize patient health and practice health. It is Zomedica's mission to provide veterinarians the opportunity to increase productivity and grow revenue while better serving the animals in their care. For more information, visit www.ZOMEDICA.com.
Follow Zomedica
Email Alerts: http://investors.zomedica.com
LinkedIn: https://www.linkedin.com/company/zomedica
Facebook: https://m.facebook.com/zomedica
Twitter: https://twitter.com/zomedica
Instagram: https://www.instagram.com/zomedica_inc
Investor Relations Contact:
RedChip Companies Inc.
Barrett Boone
This email address is being protected from spambots. You need JavaScript enabled to view it.
407-571-0912
Last Trade: | US$0.13 |
Daily Change: | -0.0013 -1.03 |
Daily Volume: | 5,901,770 |
Market Cap: | US$122.490M |
December 23, 2024 November 27, 2024 November 14, 2024 November 08, 2024 November 07, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORERecursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREEnd of content
No more pages to load